CA3054947A1 - Treatment of a disease of the gastrointestinal tract with live biotherapeutics - Google Patents

Info

Publication number

CA3054947A1

CA3054947A1 CA3054947A CA3054947A CA3054947A1 CA 3054947 A1 CA3054947 A1 CA 3054947A1 CA 3054947 A CA3054947 A CA 3054947A CA 3054947 A CA3054947 A CA 3054947A CA 3054947 A1 CA3054947 A1 CA 3054947A1

Authority

CA

Canada

Prior art keywords

ingestible device

subject

live biotherapeutic

disease

location

Prior art date

2017-03-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 210000001035 gastrointestinal tract Anatomy 0.000 title claims description 316
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 243
• 201000010099 disease Diseases 0.000 title claims description 231
• 238000011282 treatment Methods 0.000 title claims description 66
• 229940126587 biotherapeutics Drugs 0.000 title claims description 32
• 238000000034 method Methods 0.000 claims description 631
• 210000000130 stem cell Anatomy 0.000 claims description 213
• 210000004027 cell Anatomy 0.000 claims description 175
• 210000001198 duodenum Anatomy 0.000 claims description 152
• 239000000203 mixture Substances 0.000 claims description 141
• 230000008569 process Effects 0.000 claims description 132
• 210000001519 tissue Anatomy 0.000 claims description 118
• 210000001630 jejunum Anatomy 0.000 claims description 106
• 230000007246 mechanism Effects 0.000 claims description 94
• 239000008194 pharmaceutical composition Substances 0.000 claims description 86
• 238000003860 storage Methods 0.000 claims description 85
• 230000007704 transition Effects 0.000 claims description 81
• 238000009472 formulation Methods 0.000 claims description 77
• 239000003814 drug Substances 0.000 claims description 75
• 239000000126 substance Substances 0.000 claims description 75
• 210000004534 cecum Anatomy 0.000 claims description 68
• 230000004044 response Effects 0.000 claims description 67
• 208000011231 Crohn disease Diseases 0.000 claims description 63
• 210000001072 colon Anatomy 0.000 claims description 59
• 210000003405 ileum Anatomy 0.000 claims description 54
• 239000000463 material Substances 0.000 claims description 46
• 206010009887 colitis Diseases 0.000 claims description 43
• 238000004873 anchoring Methods 0.000 claims description 40
• 239000012530 fluid Substances 0.000 claims description 38
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 37
• 210000004877 mucosa Anatomy 0.000 claims description 35
• 230000003287 optical effect Effects 0.000 claims description 35
• 210000000813 small intestine Anatomy 0.000 claims description 35
• 229940079593 drug Drugs 0.000 claims description 33
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 31
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 30
• 239000003795 chemical substances by application Substances 0.000 claims description 30
• 230000007613 environmental effect Effects 0.000 claims description 29
• 210000002429 large intestine Anatomy 0.000 claims description 28
• 229940124597 therapeutic agent Drugs 0.000 claims description 27
• 238000012384 transportation and delivery Methods 0.000 claims description 27
• -1 CD70-CD27 Proteins 0.000 claims description 26
• 230000001960 triggered effect Effects 0.000 claims description 24
• 230000003902 lesion Effects 0.000 claims description 22
• 239000003550 marker Substances 0.000 claims description 20
• 239000012528 membrane Substances 0.000 claims description 20
• 239000000243 solution Substances 0.000 claims description 20
• 238000004891 communication Methods 0.000 claims description 19
• 230000004807 localization Effects 0.000 claims description 19
• 241001465754 Metazoa Species 0.000 claims description 18
• 238000001514 detection method Methods 0.000 claims description 18
• 210000004379 membrane Anatomy 0.000 claims description 18
• 210000003384 transverse colon Anatomy 0.000 claims description 16
• 239000000853 adhesive Substances 0.000 claims description 13
• 230000001070 adhesive effect Effects 0.000 claims description 13
• 210000004369 blood Anatomy 0.000 claims description 13
• 239000008280 blood Substances 0.000 claims description 13
• 210000004876 tela submucosa Anatomy 0.000 claims description 13
• 230000000694 effects Effects 0.000 claims description 12
• 238000003384 imaging method Methods 0.000 claims description 12
• 239000007788 liquid Substances 0.000 claims description 12
• 238000012544 monitoring process Methods 0.000 claims description 12
• 238000012545 processing Methods 0.000 claims description 12
• 239000007921 spray Substances 0.000 claims description 12
• 238000007910 systemic administration Methods 0.000 claims description 11
• 229920003023 plastic Polymers 0.000 claims description 10
• 239000004033 plastic Substances 0.000 claims description 10
• 210000001815 ascending colon Anatomy 0.000 claims description 9
• 210000001185 bone marrow Anatomy 0.000 claims description 9
• 230000003247 decreasing effect Effects 0.000 claims description 9
• 230000001580 bacterial effect Effects 0.000 claims description 8
• 238000002347 injection Methods 0.000 claims description 8
• 239000007924 injection Substances 0.000 claims description 8
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
• 229920001296 polysiloxane Polymers 0.000 claims description 7
• 102100022464 5'-nucleotidase Human genes 0.000 claims description 6
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 6
• 239000011248 coating agent Substances 0.000 claims description 6
• 238000000576 coating method Methods 0.000 claims description 6
• 238000001839 endoscopy Methods 0.000 claims description 6
• 230000012010 growth Effects 0.000 claims description 6
• 239000003018 immunosuppressive agent Substances 0.000 claims description 6
• 210000004400 mucous membrane Anatomy 0.000 claims description 6
• 229920000915 polyvinyl chloride Polymers 0.000 claims description 6
• 238000005086 pumping Methods 0.000 claims description 6
• 210000000664 rectum Anatomy 0.000 claims description 6
• 230000009885 systemic effect Effects 0.000 claims description 6
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
• 210000001731 descending colon Anatomy 0.000 claims description 5
• 239000003446 ligand Substances 0.000 claims description 5
• 239000004417 polycarbonate Substances 0.000 claims description 5
• 229920000515 polycarbonate Polymers 0.000 claims description 5
• 210000001599 sigmoid colon Anatomy 0.000 claims description 5
• 239000000829 suppository Substances 0.000 claims description 5
• 239000000725 suspension Substances 0.000 claims description 5
• 208000004998 Abdominal Pain Diseases 0.000 claims description 4
• 241000792859 Enema Species 0.000 claims description 4
• 108010002350 Interleukin-2 Proteins 0.000 claims description 4
• 102000000588 Interleukin-2 Human genes 0.000 claims description 4
• 238000004422 calculation algorithm Methods 0.000 claims description 4
• 230000007423 decrease Effects 0.000 claims description 4
• 230000001419 dependent effect Effects 0.000 claims description 4
• 239000007920 enema Substances 0.000 claims description 4
• 229940095399 enema Drugs 0.000 claims description 4
• 239000010935 stainless steel Substances 0.000 claims description 4
• 229910001220 stainless steel Inorganic materials 0.000 claims description 4
• 108060003951 Immunoglobulin Proteins 0.000 claims description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
• 230000004913 activation Effects 0.000 claims description 3
• 239000002246 antineoplastic agent Substances 0.000 claims description 3
• 229940127089 cytotoxic agent Drugs 0.000 claims description 3
• 239000002702 enteric coating Substances 0.000 claims description 3
• 238000009505 enteric coating Methods 0.000 claims description 3
• 210000005081 epithelial layer Anatomy 0.000 claims description 3
• 102000018358 immunoglobulin Human genes 0.000 claims description 3
• 239000002955 immunomodulating agent Substances 0.000 claims description 3
• 229940121354 immunomodulator Drugs 0.000 claims description 3
• 238000002513 implantation Methods 0.000 claims description 3
• 230000003993 interaction Effects 0.000 claims description 3
• 229910052751 metal Inorganic materials 0.000 claims description 3
• 239000002184 metal Substances 0.000 claims description 3
• 230000032258 transport Effects 0.000 claims description 3
• 102100030703 Interleukin-22 Human genes 0.000 claims description 2
• 102000004889 Interleukin-6 Human genes 0.000 claims description 2
• 108090001005 Interleukin-6 Proteins 0.000 claims description 2
• 229910045601 alloy Inorganic materials 0.000 claims description 2
• 239000000956 alloy Substances 0.000 claims description 2
• 210000001691 amnion Anatomy 0.000 claims description 2
• 210000004381 amniotic fluid Anatomy 0.000 claims description 2
• 230000005670 electromagnetic radiation Effects 0.000 claims description 2
• 230000003511 endothelial effect Effects 0.000 claims description 2
• 210000003608 fece Anatomy 0.000 claims description 2
• 230000037406 food intake Effects 0.000 claims description 2
• 230000002584 immunomodulator Effects 0.000 claims description 2
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
• 108010074109 interleukin-22 Proteins 0.000 claims description 2
• 235000015110 jellies Nutrition 0.000 claims description 2
• 239000008274 jelly Substances 0.000 claims description 2
• 229960000485 methotrexate Drugs 0.000 claims description 2
• 210000002826 placenta Anatomy 0.000 claims description 2
• 230000001105 regulatory effect Effects 0.000 claims description 2
• 230000006698 induction Effects 0.000 claims 14
• 238000012423 maintenance Methods 0.000 claims 10
• 239000000090 biomarker Substances 0.000 claims 9
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 7
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 7
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 7
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 7
• 229940045207 immuno-oncology agent Drugs 0.000 claims 7
• 239000002584 immunological anticancer agent Substances 0.000 claims 7
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 6
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 6
• 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
• 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 5
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 5
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 5
• 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims 4
• 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 4
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 3
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 3
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
• 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 3
• 101710092458 Lymphocyte activation gene 3 protein Proteins 0.000 claims 3
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
• 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
• 102100024263 CD160 antigen Human genes 0.000 claims 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
• 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
• 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 2
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
• 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims 2
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
• 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims 2
• 230000015556 catabolic process Effects 0.000 claims 2
• 230000000973 chemotherapeutic effect Effects 0.000 claims 2
• 238000006731 degradation reaction Methods 0.000 claims 2
• 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 2
• 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
• 229960003301 nivolumab Drugs 0.000 claims 2
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
• 108010072524 BKT140 Proteins 0.000 claims 1
• 229940125565 BMS-986016 Drugs 0.000 claims 1
• 102100025429 Butyrophilin-like protein 2 Human genes 0.000 claims 1
• 108010017533 Butyrophilins Proteins 0.000 claims 1
• 102000004555 Butyrophilins Human genes 0.000 claims 1
• 102100027207 CD27 antigen Human genes 0.000 claims 1
• 108010029697 CD40 Ligand Proteins 0.000 claims 1
• 101150013553 CD40 gene Proteins 0.000 claims 1
• 102100032937 CD40 ligand Human genes 0.000 claims 1
• 102100036008 CD48 antigen Human genes 0.000 claims 1
• 102100029382 CMRF35-like molecule 6 Human genes 0.000 claims 1
• 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
• 108010069514 Cyclic Peptides Proteins 0.000 claims 1
• 102000001189 Cyclic Peptides Human genes 0.000 claims 1
• 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 1
• 102100031351 Galectin-9 Human genes 0.000 claims 1
• 101710121810 Galectin-9 Proteins 0.000 claims 1
• 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 1
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
• 101000934738 Homo sapiens Butyrophilin-like protein 2 Proteins 0.000 claims 1
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 1
• 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 claims 1
• 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 1
• 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims 1
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
• 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 1
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
• 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
• 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
• 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
• 102000013691 Interleukin-17 Human genes 0.000 claims 1
• 108050003558 Interleukin-17 Proteins 0.000 claims 1
• 108020003285 Isocitrate lyase Proteins 0.000 claims 1
• 102000002698 KIR Receptors Human genes 0.000 claims 1
• 108010043610 KIR Receptors Proteins 0.000 claims 1
• 101150069255 KLRC1 gene Proteins 0.000 claims 1
• IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 claims 1
• 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims 1
• 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims 1
• 108091054438 MHC class II family Proteins 0.000 claims 1
• 102000043131 MHC class II family Human genes 0.000 claims 1
• 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 1
• 108010008701 Mucin-3 Proteins 0.000 claims 1
• 102000007295 Mucin-3 Human genes 0.000 claims 1
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
• 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 1
• FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims 1
• 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 1
• 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
• 102000002111 Neuropilin Human genes 0.000 claims 1
• 108050009450 Neuropilin Proteins 0.000 claims 1
• 229940116355 PI3 kinase inhibitor Drugs 0.000 claims 1
• 101150012848 PVR gene Proteins 0.000 claims 1
• 102100029740 Poliovirus receptor Human genes 0.000 claims 1
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
• 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims 1
• 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims 1
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
• 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
• 229960003852 atezolizumab Drugs 0.000 claims 1
• 229950002916 avelumab Drugs 0.000 claims 1
• 229950007843 bavituximab Drugs 0.000 claims 1
• 229960000397 bevacizumab Drugs 0.000 claims 1
• 239000013256 coordination polymer Substances 0.000 claims 1
• 229950009791 durvalumab Drugs 0.000 claims 1
• 229950004647 emactuzumab Drugs 0.000 claims 1
• 230000002255 enzymatic effect Effects 0.000 claims 1
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
• 235000012631 food intake Nutrition 0.000 claims 1
• 229950000456 galunisertib Drugs 0.000 claims 1
• 230000002519 immonomodulatory effect Effects 0.000 claims 1
• 230000001861 immunosuppressant effect Effects 0.000 claims 1
• 229960005386 ipilimumab Drugs 0.000 claims 1
• 229950011263 lirilumab Drugs 0.000 claims 1
• JJVZSYKFCOBILL-MKMRYRNGSA-N motixafortide Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)c1ccc(F)cc1 JJVZSYKFCOBILL-MKMRYRNGSA-N 0.000 claims 1
• 229960002621 pembrolizumab Drugs 0.000 claims 1
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
• 108010048507 poliovirus receptor Proteins 0.000 claims 1
• 229950007213 spartalizumab Drugs 0.000 claims 1
• 230000001131 transforming effect Effects 0.000 claims 1
• 229950007217 tremelimumab Drugs 0.000 claims 1
• 229950010095 ulocuplumab Drugs 0.000 claims 1
• 229950005972 urelumab Drugs 0.000 claims 1
• 229950001067 varlilumab Drugs 0.000 claims 1
• 210000002784 stomach Anatomy 0.000 description 164
• 239000007789 gas Substances 0.000 description 82
• 238000005259 measurement Methods 0.000 description 76
• 230000004118 muscle contraction Effects 0.000 description 67
• ZLGYJAIAVPVCNF-UHFFFAOYSA-N 1,2,4-trichloro-5-(3,5-dichlorophenyl)benzene Chemical compound ClC1=CC(Cl)=CC(C=2C(=CC(Cl)=C(Cl)C=2)Cl)=C1 ZLGYJAIAVPVCNF-UHFFFAOYSA-N 0.000 description 50
• 238000005286 illumination Methods 0.000 description 50
• 241000894006 Bacteria Species 0.000 description 39
• 241000282898 Sus scrofa Species 0.000 description 35
• 230000002572 peristaltic effect Effects 0.000 description 35
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 34
• TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 33
• 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 33
• 239000002775 capsule Substances 0.000 description 33
• 230000033001 locomotion Effects 0.000 description 28
• 241000894007 species Species 0.000 description 28
• 239000002609 medium Substances 0.000 description 27
• 238000010586 diagram Methods 0.000 description 26
• 230000000968 intestinal effect Effects 0.000 description 26
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 25
• 229960001967 tacrolimus Drugs 0.000 description 25
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 25
• 239000003981 vehicle Substances 0.000 description 24
• 210000000577 adipose tissue Anatomy 0.000 description 23
• 241001515965 unidentified phage Species 0.000 description 23
• 241000699670 Mus sp. Species 0.000 description 22
• 239000000523 sample Substances 0.000 description 22
• 238000012360 testing method Methods 0.000 description 22
• 229960002964 adalimumab Drugs 0.000 description 21
• 206010071061 Small intestinal bacterial overgrowth Diseases 0.000 description 20
• 230000007142 small intestinal bacterial overgrowth Effects 0.000 description 20
• 238000001228 spectrum Methods 0.000 description 20
• 238000005070 sampling Methods 0.000 description 18
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 17
• 108010036949 Cyclosporine Proteins 0.000 description 17
• 238000000692 Student's t-test Methods 0.000 description 17
• 238000007619 statistical method Methods 0.000 description 17
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
• 208000025865 Ulcer Diseases 0.000 description 16
• 210000003238 esophagus Anatomy 0.000 description 16
• 230000000670 limiting effect Effects 0.000 description 16
• 206010061218 Inflammation Diseases 0.000 description 15
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 15
• 230000001154 acute effect Effects 0.000 description 15
• 230000004054 inflammatory process Effects 0.000 description 15
• 229930105110 Cyclosporin A Natural products 0.000 description 14
• 230000002496 gastric effect Effects 0.000 description 14
• 208000024891 symptom Diseases 0.000 description 14
• 230000003204 osmotic effect Effects 0.000 description 13
• 239000003242 anti bacterial agent Substances 0.000 description 12
• 230000008859 change Effects 0.000 description 12
• 208000035475 disorder Diseases 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 239000003937 drug carrier Substances 0.000 description 10
• 229940027941 immunoglobulin g Drugs 0.000 description 10
• 230000000737 periodic effect Effects 0.000 description 10
• 230000002441 reversible effect Effects 0.000 description 10
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 230000003115 biocidal effect Effects 0.000 description 9
• 150000001875 compounds Chemical class 0.000 description 9
• 238000012377 drug delivery Methods 0.000 description 9
• 239000001257 hydrogen Substances 0.000 description 9
• 229910052739 hydrogen Inorganic materials 0.000 description 9
• 210000004263 induced pluripotent stem cell Anatomy 0.000 description 9
• 208000002551 irritable bowel syndrome Diseases 0.000 description 9
• 239000006041 probiotic Substances 0.000 description 9
• 235000018291 probiotics Nutrition 0.000 description 9
• 229940126585 therapeutic drug Drugs 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 231100000397 ulcer Toxicity 0.000 description 9
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
• 208000018522 Gastrointestinal disease Diseases 0.000 description 8
• 230000002757 inflammatory effect Effects 0.000 description 8
• 210000000936 intestine Anatomy 0.000 description 8
• 229920000642 polymer Polymers 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 238000001356 surgical procedure Methods 0.000 description 8
• 206010012735 Diarrhoea Diseases 0.000 description 7
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 7
• 229940121375 antifungal agent Drugs 0.000 description 7
• 239000003429 antifungal agent Substances 0.000 description 7
• 239000003613 bile acid Substances 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 238000003745 diagnosis Methods 0.000 description 7
• 239000003085 diluting agent Substances 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 210000004966 intestinal stem cell Anatomy 0.000 description 7
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 210000002220 organoid Anatomy 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 210000002536 stromal cell Anatomy 0.000 description 7
• 230000036269 ulceration Effects 0.000 description 7
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
• 102100037241 Endoglin Human genes 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 102000044591 ErbB-4 Receptor Human genes 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
• 101000881679 Homo sapiens Endoglin Proteins 0.000 description 6
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 6
• 239000000556 agonist Substances 0.000 description 6
• 235000010443 alginic acid Nutrition 0.000 description 6
• 229920000615 alginic acid Polymers 0.000 description 6
• 229940088710 antibiotic agent Drugs 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 230000009286 beneficial effect Effects 0.000 description 6
• 238000012258 culturing Methods 0.000 description 6
• 238000013461 design Methods 0.000 description 6
• 230000001627 detrimental effect Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 239000003102 growth factor Substances 0.000 description 6
• 239000000017 hydrogel Substances 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 6
• 229940068196 placebo Drugs 0.000 description 6
• 239000000902 placebo Substances 0.000 description 6
• 235000018102 proteins Nutrition 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 108091006146 Channels Proteins 0.000 description 5
• 241000193403 Clostridium Species 0.000 description 5
• 208000015943 Coeliac disease Diseases 0.000 description 5
• 108010073385 Fibrin Proteins 0.000 description 5
• 102000009123 Fibrin Human genes 0.000 description 5
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
• 206010016654 Fibrosis Diseases 0.000 description 5
• 241000233866 Fungi Species 0.000 description 5
• 102000003886 Glycoproteins Human genes 0.000 description 5
• 108090000288 Glycoproteins Proteins 0.000 description 5
• 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 5
• 241000186660 Lactobacillus Species 0.000 description 5
• 102400000055 Neuregulin-4 Human genes 0.000 description 5
• 101800002641 Neuregulin-4 Proteins 0.000 description 5
• 208000002193 Pain Diseases 0.000 description 5
• 208000031481 Pathologic Constriction Diseases 0.000 description 5
• 108010087999 Steryl-Sulfatase Proteins 0.000 description 5
• 102100038021 Steryl-sulfatase Human genes 0.000 description 5
• 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 5
• 206010000269 abscess Diseases 0.000 description 5
• 230000001464 adherent effect Effects 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 229940121363 anti-inflammatory agent Drugs 0.000 description 5
• 239000002260 anti-inflammatory agent Substances 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 235000010980 cellulose Nutrition 0.000 description 5
• 229920002678 cellulose Polymers 0.000 description 5
• 239000001913 cellulose Substances 0.000 description 5
• 208000019425 cirrhosis of liver Diseases 0.000 description 5
• 230000001143 conditioned effect Effects 0.000 description 5
• 230000008602 contraction Effects 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 210000000981 epithelium Anatomy 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 229950003499 fibrin Drugs 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 230000002209 hydrophobic effect Effects 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 210000003205 muscle Anatomy 0.000 description 5
• 239000002121 nanofiber Substances 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 239000004800 polyvinyl chloride Substances 0.000 description 5
• 235000013406 prebiotics Nutrition 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 210000003289 regulatory T cell Anatomy 0.000 description 5
• 230000004043 responsiveness Effects 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 238000011269 treatment regimen Methods 0.000 description 5
• 238000001429 visible spectrum Methods 0.000 description 5
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
• 241000186000 Bifidobacterium Species 0.000 description 4
• 102000008186 Collagen Human genes 0.000 description 4
• 108010035532 Collagen Proteins 0.000 description 4
• 102000029816 Collagenase Human genes 0.000 description 4
• 108060005980 Collagenase Proteins 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 206010016717 Fistula Diseases 0.000 description 4
• 208000007882 Gastritis Diseases 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
• 240000001046 Lactobacillus acidophilus Species 0.000 description 4
• 244000199885 Lactobacillus bulgaricus Species 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 4
• 102000003729 Neprilysin Human genes 0.000 description 4
• 108090000028 Neprilysin Proteins 0.000 description 4
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 229940072056 alginate Drugs 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 239000003793 antidiarrheal agent Substances 0.000 description 4
• 235000010323 ascorbic acid Nutrition 0.000 description 4
• 229960005070 ascorbic acid Drugs 0.000 description 4
• 239000011668 ascorbic acid Substances 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 229960002170 azathioprine Drugs 0.000 description 4
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 4
• 230000027455 binding Effects 0.000 description 4
• 230000005540 biological transmission Effects 0.000 description 4
• 238000001574 biopsy Methods 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000002659 cell therapy Methods 0.000 description 4
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
• 229920001436 collagen Polymers 0.000 description 4
• 229960002424 collagenase Drugs 0.000 description 4
• 238000004590 computer program Methods 0.000 description 4
• 239000003636 conditioned culture medium Substances 0.000 description 4
• 210000004921 distal colon Anatomy 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 230000003890 fistula Effects 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229940014259 gelatin Drugs 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 230000035876 healing Effects 0.000 description 4
• 230000005847 immunogenicity Effects 0.000 description 4
• 229940125721 immunosuppressive agent Drugs 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 210000004969 inflammatory cell Anatomy 0.000 description 4
• 238000002329 infrared spectrum Methods 0.000 description 4
• 239000008297 liquid dosage form Substances 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 239000003094 microcapsule Substances 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 230000036470 plasma concentration Effects 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 229910001285 shape-memory alloy Inorganic materials 0.000 description 4
• 239000004055 small Interfering RNA Substances 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 229940083542 sodium Drugs 0.000 description 4
• 235000015424 sodium Nutrition 0.000 description 4
• 239000007909 solid dosage form Substances 0.000 description 4
• 230000036262 stenosis Effects 0.000 description 4
• 208000037804 stenosis Diseases 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 230000002459 sustained effect Effects 0.000 description 4
• 239000001993 wax Substances 0.000 description 4
• CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 3
• 238000012815 AlphaLISA Methods 0.000 description 3
• 102100022749 Aminopeptidase N Human genes 0.000 description 3
• 101100137546 Arabidopsis thaliana PRF2 gene Proteins 0.000 description 3
• 102100032912 CD44 antigen Human genes 0.000 description 3
• 206010008635 Cholestasis Diseases 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 102100023795 Elafin Human genes 0.000 description 3
• 241000192125 Firmicutes Species 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 206010018691 Granuloma Diseases 0.000 description 3
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 3
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
• 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 3
• 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 3
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
• 101000658574 Homo sapiens Transmembrane 4 L6 family member 1 Proteins 0.000 description 3
• 102100032816 Integrin alpha-6 Human genes 0.000 description 3
• 102100025304 Integrin beta-1 Human genes 0.000 description 3
• 206010025476 Malabsorption Diseases 0.000 description 3
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 3
• 206010028116 Mucosal inflammation Diseases 0.000 description 3
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• 108010058846 Ovalbumin Proteins 0.000 description 3
• 101150004094 PRO2 gene Proteins 0.000 description 3
• 206010038063 Rectal haemorrhage Diseases 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 3
• 206010052428 Wound Diseases 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 230000000735 allogeneic effect Effects 0.000 description 3
• 230000000845 anti-microbial effect Effects 0.000 description 3
• 229940125714 antidiarrheal agent Drugs 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 239000003124 biologic agent Substances 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 229960000074 biopharmaceutical Drugs 0.000 description 3
• 230000000740 bleeding effect Effects 0.000 description 3
• 210000000601 blood cell Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 3
• 229910002092 carbon dioxide Inorganic materials 0.000 description 3
• 239000002738 chelating agent Substances 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000002052 colonoscopy Methods 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• 229920001577 copolymer Polymers 0.000 description 3
• 229930182912 cyclosporin Natural products 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 208000010643 digestive system disease Diseases 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 230000009266 disease activity Effects 0.000 description 3
• 210000001671 embryonic stem cell Anatomy 0.000 description 3
• 208000037902 enteropathy Diseases 0.000 description 3
• 230000003628 erosive effect Effects 0.000 description 3
• 210000003743 erythrocyte Anatomy 0.000 description 3
• 239000005038 ethylene vinyl acetate Substances 0.000 description 3
• 210000004700 fetal blood Anatomy 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 208000018685 gastrointestinal system disease Diseases 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 238000005534 hematocrit Methods 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 208000027138 indeterminate colitis Diseases 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000002458 infectious effect Effects 0.000 description 3
• 229960000598 infliximab Drugs 0.000 description 3
• 208000028774 intestinal disease Diseases 0.000 description 3
• 235000013980 iron oxide Nutrition 0.000 description 3
• 239000012669 liquid formulation Substances 0.000 description 3
• 208000019423 liver disease Diseases 0.000 description 3
• 238000011068 loading method Methods 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 230000002101 lytic effect Effects 0.000 description 3
• 229960001428 mercaptopurine Drugs 0.000 description 3
• 210000000713 mesentery Anatomy 0.000 description 3
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
• 230000000813 microbial effect Effects 0.000 description 3
• 238000001000 micrograph Methods 0.000 description 3
• 210000000214 mouth Anatomy 0.000 description 3
• 229940092253 ovalbumin Drugs 0.000 description 3
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 229960003742 phenol Drugs 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
• 229920000728 polyester Polymers 0.000 description 3
• 239000004633 polyglycolic acid Substances 0.000 description 3
• 229950008885 polyglycolic acid Drugs 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000000529 probiotic effect Effects 0.000 description 3
• 238000002271 resection Methods 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 150000004666 short chain fatty acids Chemical class 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 210000001082 somatic cell Anatomy 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000013589 supplement Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000002604 ultrasonography Methods 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 230000036642 wellbeing Effects 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 description 2
• HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
• 206010000060 Abdominal distension Diseases 0.000 description 2
• 206010000077 Abdominal mass Diseases 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 241001156739 Actinobacteria <phylum> Species 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 241000605059 Bacteroidetes Species 0.000 description 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
• 108091033409 CRISPR Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 208000014997 Crohn colitis Diseases 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 239000004803 Di-2ethylhexylphthalate Substances 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 206010058838 Enterocolitis infectious Diseases 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 239000001856 Ethyl cellulose Substances 0.000 description 2
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
• 241000186394 Eubacterium Species 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 241000605980 Faecalibacterium prausnitzii Species 0.000 description 2
• 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
• 208000001640 Fibromyalgia Diseases 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 241000287227 Fringillidae Species 0.000 description 2
• 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
• 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 description 2
• 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 2
• 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 208000031886 HIV Infections Diseases 0.000 description 2
• 208000037357 HIV infectious disease Diseases 0.000 description 2
• 101001048718 Homo sapiens Elafin Proteins 0.000 description 2
• 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 2
• 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010021518 Impaired gastric emptying Diseases 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
• 229920001202 Inulin Polymers 0.000 description 2
• 102100020677 Krueppel-like factor 4 Human genes 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• 240000006024 Lactobacillus plantarum Species 0.000 description 2
• 241000186604 Lactobacillus reuteri Species 0.000 description 2
• 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 108010000817 Leuprolide Proteins 0.000 description 2
• 208000002720 Malnutrition Diseases 0.000 description 2
• 201000010927 Mucositis Diseases 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
• 206010033649 Pancreatitis chronic Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 229920002732 Polyanhydride Polymers 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• 241001303601 Rosacea Species 0.000 description 2
• 241000192031 Ruminococcus Species 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 206010039897 Sedation Diseases 0.000 description 2
• 108010071390 Serum Albumin Proteins 0.000 description 2
• 102000007562 Serum Albumin Human genes 0.000 description 2
• 108091027967 Small hairpin RNA Proteins 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 241000194020 Streptococcus thermophilus Species 0.000 description 2
• 102000019197 Superoxide Dismutase Human genes 0.000 description 2
• 108010012715 Superoxide dismutase Proteins 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000009858 acid secretion Effects 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000006978 adaptation Effects 0.000 description 2
• 210000000593 adipose tissue white Anatomy 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
• 229960003942 amphotericin b Drugs 0.000 description 2
• 206010002156 anal fistula Diseases 0.000 description 2
• 230000003872 anastomosis Effects 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 210000000436 anus Anatomy 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• 229960004217 benzyl alcohol Drugs 0.000 description 2
• 239000012620 biological material Substances 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 2
• 208000024330 bloating Diseases 0.000 description 2
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
• XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000001569 carbon dioxide Substances 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 229960004926 chlorobutanol Drugs 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 210000001612 chondrocyte Anatomy 0.000 description 2
• 208000020832 chronic kidney disease Diseases 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 238000012321 colectomy Methods 0.000 description 2
• 230000001332 colony forming effect Effects 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 239000002131 composite material Substances 0.000 description 2
• 208000018631 connective tissue disease Diseases 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 239000003405 delayed action preparation Substances 0.000 description 2
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 208000028208 end stage renal disease Diseases 0.000 description 2
• 201000000523 end stage renal failure Diseases 0.000 description 2
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
• 235000019325 ethyl cellulose Nutrition 0.000 description 2
• 229920001249 ethyl cellulose Polymers 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
• 150000003271 galactooligosaccharides Chemical class 0.000 description 2
• 208000001288 gastroparesis Diseases 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 244000005709 gut microbiome Species 0.000 description 2
• 102000046949 human MSC Human genes 0.000 description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
• 229920001477 hydrophilic polymer Polymers 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 208000003532 hypothyroidism Diseases 0.000 description 2
• 230000002989 hypothyroidism Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 208000027139 infectious colitis Diseases 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940076144 interleukin-10 Drugs 0.000 description 2
• 230000007358 intestinal barrier function Effects 0.000 description 2
• 229940029339 inulin Drugs 0.000 description 2
• JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
• HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 2
• YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
• 238000007443 liposuction Methods 0.000 description 2
• 229960001571 loperamide Drugs 0.000 description 2
• RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 230000001071 malnutrition Effects 0.000 description 2
• 235000000824 malnutrition Nutrition 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
• 229960002216 methylparaben Drugs 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 208000008275 microscopic colitis Diseases 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000003232 mucoadhesive effect Effects 0.000 description 2
• 210000003097 mucus Anatomy 0.000 description 2
• 201000006938 muscular dystrophy Diseases 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• 229960005027 natalizumab Drugs 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
• 235000021140 nondigestible carbohydrates Nutrition 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 208000015380 nutritional deficiency disease Diseases 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 229920001542 oligosaccharide Polymers 0.000 description 2
• 150000002482 oligosaccharides Chemical class 0.000 description 2
• NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 235000016236 parenteral nutrition Nutrition 0.000 description 2
• AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 210000004180 plasmocyte Anatomy 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 239000004626 polylactic acid Substances 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 150000004804 polysaccharides Chemical class 0.000 description 2
• 229920002635 polyurethane Polymers 0.000 description 2
• 239000004814 polyurethane Substances 0.000 description 2
• 229920002451 polyvinyl alcohol Polymers 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 238000001223 reverse osmosis Methods 0.000 description 2
• 201000004700 rosacea Diseases 0.000 description 2
• 230000036280 sedation Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 229960001866 silicon dioxide Drugs 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 230000003595 spectral effect Effects 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 229940032147 starch Drugs 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 230000008093 supporting effect Effects 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 229940033134 talc Drugs 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
• 229940033663 thimerosal Drugs 0.000 description 2
• 201000002516 toxic megacolon Diseases 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• 238000002211 ultraviolet spectrum Methods 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 229960004914 vedolizumab Drugs 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• 239000012855 volatile organic compound Substances 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
• BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
• RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
• WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
• OBFSQMXGZIYMMN-UHFFFAOYSA-N 3-chloro-2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=NC=CC=C1Cl OBFSQMXGZIYMMN-UHFFFAOYSA-N 0.000 description 1
• RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
• WXFIFTYQCGZRGR-UHFFFAOYSA-N 5-hydroxy-2-methylhex-2-enamide Chemical compound CC(O)CC=C(C)C(N)=O WXFIFTYQCGZRGR-UHFFFAOYSA-N 0.000 description 1
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
• WIYVVIUBKNTNKG-UHFFFAOYSA-N 6,7-dimethoxy-3,4-dihydronaphthalene-2-carboxylic acid Chemical compound C1CC(C(O)=O)=CC2=C1C=C(OC)C(OC)=C2 WIYVVIUBKNTNKG-UHFFFAOYSA-N 0.000 description 1
• 206010000084 Abdominal pain lower Diseases 0.000 description 1
• 206010000159 Abnormal loss of weight Diseases 0.000 description 1
• 241000203809 Actinomycetales Species 0.000 description 1
• 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 241000511612 Anaerofilum Species 0.000 description 1
• 108010064760 Anidulafungin Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 101100137548 Arabidopsis thaliana PRF4 gene Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 241001661602 Bacillus infantis Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 241000606124 Bacteroides fragilis Species 0.000 description 1
• 241000606215 Bacteroides vulgatus Species 0.000 description 1
• 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
• 241001134770 Bifidobacterium animalis Species 0.000 description 1
• 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
• 206010069703 Bile acid malabsorption Diseases 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 241000605902 Butyrivibrio Species 0.000 description 1
• 102000000584 Calmodulin Human genes 0.000 description 1
• 108010041952 Calmodulin Proteins 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000222178 Candida tropicalis Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 108010020326 Caspofungin Proteins 0.000 description 1
• 241001137855 Caudovirales Species 0.000 description 1
• 101150015280 Cel gene Proteins 0.000 description 1
• 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
• 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• 239000004380 Cholic acid Substances 0.000 description 1
• 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
• 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 241001112696 Clostridia Species 0.000 description 1
• 241000193163 Clostridioides difficile Species 0.000 description 1
• 241000193171 Clostridium butyricum Species 0.000 description 1
• 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
• 206010009895 Colitis ischaemic Diseases 0.000 description 1
• 241001464948 Coprococcus Species 0.000 description 1
• 241001657523 Coriobacteriaceae Species 0.000 description 1
• 241001662464 Coriobacteriales Species 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 229920001651 Cyanoacrylate Polymers 0.000 description 1
• 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 241001624700 Dialister invisus Species 0.000 description 1
• 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010013530 Diverticula Diseases 0.000 description 1
• 206010013554 Diverticulum Diseases 0.000 description 1
• 241001143779 Dorea Species 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 108010049047 Echinocandins Proteins 0.000 description 1
• 241001657509 Eggerthella Species 0.000 description 1
• 108010015972 Elafin Proteins 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 229940121818 ErbB-4 agonist Drugs 0.000 description 1
• 206010015226 Erythema nodosum Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 208000034347 Faecal incontinence Diseases 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 108010040721 Flagellin Proteins 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• 241001453172 Fusobacteria Species 0.000 description 1
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
• 241000193789 Gemella Species 0.000 description 1
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 108010034145 Helminth Proteins Proteins 0.000 description 1
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
• 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
• 206010019708 Hepatic steatosis Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 1
• 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
• 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 1
• 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
• 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 108010003272 Hyaluronate lyase Proteins 0.000 description 1
• 102000001974 Hyaluronidases Human genes 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 206010020601 Hyperchlorhydria Diseases 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 206010021460 Immunodeficiency syndromes Diseases 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 238000012695 Interfacial polymerization Methods 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• 108700003486 Jagged-1 Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 101150017554 LGR5 gene Proteins 0.000 description 1
• 241001134638 Lachnospira Species 0.000 description 1
• 241001112693 Lachnospiraceae Species 0.000 description 1
• 244000199866 Lactobacillus casei Species 0.000 description 1
• 241000186605 Lactobacillus paracasei Species 0.000 description 1
• 108010063045 Lactoferrin Proteins 0.000 description 1
• 102000010445 Lactoferrin Human genes 0.000 description 1
• 102000007547 Laminin Human genes 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
• 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
• SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 239000004907 Macro-emulsion Substances 0.000 description 1
• YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
• MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 108010021062 Micafungin Proteins 0.000 description 1
• 241000736262 Microbiota Species 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000702318 Microviridae Species 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010051606 Necrotising colitis Diseases 0.000 description 1
• 206010055668 Necrotising oesophagitis Diseases 0.000 description 1
• 241000909283 Negativicutes Species 0.000 description 1
• 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 241000906034 Orthops Species 0.000 description 1
• 241000366596 Osiris Species 0.000 description 1
• 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
• 101150066369 PRO3 gene Proteins 0.000 description 1
• 241000599931 Paris quadrifolia Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 241000425347 Phyla <beetle> Species 0.000 description 1
• 241000702072 Podoviridae Species 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 208000002389 Pouchitis Diseases 0.000 description 1
• 102100040918 Pro-glucagon Human genes 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
• 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
• 208000006311 Pyoderma Diseases 0.000 description 1
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
• 102100034026 RNA-binding protein Musashi homolog 1 Human genes 0.000 description 1
• 101710129077 RNA-binding protein Musashi homolog 1 Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 241000269435 Rana <genus> Species 0.000 description 1
• 229920000297 Rayon Polymers 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 206010057071 Rectal tenesmus Diseases 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 241000605947 Roseburia Species 0.000 description 1
• 241000872832 Roseburia hominis Species 0.000 description 1
• 241000192029 Ruminococcus albus Species 0.000 description 1
• 241000123753 Ruminococcus bromii Species 0.000 description 1
• 241000123754 Ruminococcus callidus Species 0.000 description 1
• 101700026522 SMAD7 Proteins 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 241000242678 Schistosoma Species 0.000 description 1
• 206010062164 Seronegative arthritis Diseases 0.000 description 1
• 241000607715 Serratia marcescens Species 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 241000702202 Siphoviridae Species 0.000 description 1
• 241001657520 Slackia Species 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 108010073771 Soybean Proteins Proteins 0.000 description 1
• 241000239110 Staphylococcus virus K Species 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 206010042220 Stress ulcer Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 208000033809 Suppuration Diseases 0.000 description 1
• 201000008736 Systemic mastocytosis Diseases 0.000 description 1
• 241000534944 Thia Species 0.000 description 1
• 229920002807 Thiomer Polymers 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108010007389 Trefoil Factors Proteins 0.000 description 1
• 102000007641 Trefoil Factors Human genes 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 229920000690 Tyvek Polymers 0.000 description 1
• 239000004775 Tyvek Substances 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
• 241001531188 [Eubacterium] rectale Species 0.000 description 1
• 206010000059 abdominal discomfort Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
• 239000003929 acidic solution Substances 0.000 description 1
• 229920006397 acrylic thermoplastic Polymers 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 210000003486 adipose tissue brown Anatomy 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 210000004504 adult stem cell Anatomy 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229940009827 aluminum acetate Drugs 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 229960003348 anidulafungin Drugs 0.000 description 1
• JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000002421 anti-septic effect Effects 0.000 description 1
• 230000002137 anti-vascular effect Effects 0.000 description 1
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 208000002399 aphthous stomatitis Diseases 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000013011 aqueous formulation Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 238000009529 body temperature measurement Methods 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
• 229940067596 butylparaben Drugs 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 235000010410 calcium alginate Nutrition 0.000 description 1
• 239000000648 calcium alginate Substances 0.000 description 1
• 229960002681 calcium alginate Drugs 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
• 235000011188 calcium disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
• SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 239000004204 candelilla wax Substances 0.000 description 1
• 229940073532 candelilla wax Drugs 0.000 description 1
• 235000013868 candelilla wax Nutrition 0.000 description 1
• 239000003990 capacitor Substances 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000002041 carbon nanotube Substances 0.000 description 1
• 229910021393 carbon nanotube Inorganic materials 0.000 description 1
• 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 229960003034 caspofungin Drugs 0.000 description 1
• JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 238000000701 chemical imaging Methods 0.000 description 1
• RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
• 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
• 230000007870 cholestasis Effects 0.000 description 1
• 231100000359 cholestasis Toxicity 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 235000019416 cholic acid Nutrition 0.000 description 1
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
• 229960002471 cholic acid Drugs 0.000 description 1
• 210000004252 chorionic villi Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000019902 chronic diarrheal disease Diseases 0.000 description 1
• 208000016532 chronic granulomatous disease Diseases 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000005354 coacervation Methods 0.000 description 1
• 238000004581 coalescence Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 208000008609 collagenous colitis Diseases 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 239000002322 conducting polymer Substances 0.000 description 1
• 229920001940 conductive polymer Polymers 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000011443 conventional therapy Methods 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 238000013500 data storage Methods 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 210000003074 dental pulp Anatomy 0.000 description 1
• 210000001968 dental pulp cell Anatomy 0.000 description 1
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 231100000223 dermal penetration Toxicity 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 102000038379 digestive enzymes Human genes 0.000 description 1
• 108091007734 digestive enzymes Proteins 0.000 description 1
• 229940008099 dimethicone Drugs 0.000 description 1
• 239000004205 dimethyl polysiloxane Substances 0.000 description 1
• 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
• 229960004192 diphenoxylate Drugs 0.000 description 1
• HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• IVKWXPBUMQZFCW-UHFFFAOYSA-L disodium;2-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate;hydrate Chemical compound O.[Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IVKWXPBUMQZFCW-UHFFFAOYSA-L 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 201000008243 diversion colitis Diseases 0.000 description 1
• 208000007784 diverticulitis Diseases 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 201000006549 dyspepsia Diseases 0.000 description 1
• 210000003981 ectoderm Anatomy 0.000 description 1
• 230000002497 edematous effect Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 239000000806 elastomer Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000001900 endoderm Anatomy 0.000 description 1
• 238000001861 endoscopic biopsy Methods 0.000 description 1
• 238000002674 endoscopic surgery Methods 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 238000004146 energy storage Methods 0.000 description 1
• 208000010227 enterocolitis Diseases 0.000 description 1
• 210000001842 enterocyte Anatomy 0.000 description 1
• 230000006862 enzymatic digestion Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
• 229940080322 erythrosine sodium Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 230000001076 estrogenic effect Effects 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• 229960004667 ethyl cellulose Drugs 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000011124 ex vivo culture Methods 0.000 description 1
• 238000004880 explosion Methods 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 208000010706 fatty liver disease Diseases 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 206010016766 flatulence Diseases 0.000 description 1
• 229920002313 fluoropolymer Polymers 0.000 description 1
• 239000004811 fluoropolymer Substances 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 230000027119 gastric acid secretion Effects 0.000 description 1
• 210000004051 gastric juice Anatomy 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 208000018925 gastrointestinal mucositis Diseases 0.000 description 1
• 230000008570 general process Effects 0.000 description 1
• 210000001654 germ layer Anatomy 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229940049654 glyceryl behenate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• 229960002773 hyaluronidase Drugs 0.000 description 1
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
• 229940044700 hylenex Drugs 0.000 description 1
• 229960003943 hypromellose Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 208000033065 inborn errors of immunity Diseases 0.000 description 1
• 208000016245 inborn errors of metabolism Diseases 0.000 description 1
• 238000011419 induction treatment Methods 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 208000015978 inherited metabolic disease Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 230000031261 interleukin-10 production Effects 0.000 description 1
• 229940117681 interleukin-12 Drugs 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 201000008222 ischemic colitis Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 229940039696 lactobacillus Drugs 0.000 description 1
• 229940078795 lactoferrin Drugs 0.000 description 1
• 235000021242 lactoferrin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 201000008105 leukocyte adhesion deficiency 1 Diseases 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 229920006008 lipopolysaccharide Polymers 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 230000001320 lysogenic effect Effects 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 229960001708 magnesium carbonate Drugs 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• 229960000869 magnesium oxide Drugs 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 238000009115 maintenance therapy Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 235000015875 medicated confectionery Nutrition 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229940126601 medicinal product Drugs 0.000 description 1
• 229960003987 melatonin Drugs 0.000 description 1
• DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
• 229960004963 mesalazine Drugs 0.000 description 1
• 210000003716 mesoderm Anatomy 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 229910044991 metal oxide Inorganic materials 0.000 description 1
• 150000004706 metal oxides Chemical class 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
• 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002159 micafungin Drugs 0.000 description 1
• PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 229940042472 mineral oil Drugs 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 229910003455 mixed metal oxide Inorganic materials 0.000 description 1
• 230000001483 mobilizing effect Effects 0.000 description 1
• 239000002991 molded plastic Substances 0.000 description 1
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
• RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 238000004264 monolayer culture Methods 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 230000002969 morbid Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000002894 multi-fate stem cell Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 108010032539 nartograstim Proteins 0.000 description 1
• 229950010676 nartograstim Drugs 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 108700007229 noggin Proteins 0.000 description 1
• 102000045246 noggin Human genes 0.000 description 1
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 229940100692 oral suspension Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 238000001139 pH measurement Methods 0.000 description 1
• 210000003134 paneth cell Anatomy 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 238000009832 plasma treatment Methods 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 239000006223 plastic coating Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229920006267 polyester film Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 229920000098 polyolefin Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 238000005381 potential energy Methods 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
• BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
• 210000004915 pus Anatomy 0.000 description 1
• 210000001187 pylorus Anatomy 0.000 description 1
• 238000003380 quartz crystal microbalance Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 239000002964 rayon Substances 0.000 description 1
• 238000001454 recorded image Methods 0.000 description 1
• 231100000272 reduced body weight Toxicity 0.000 description 1
• 238000007670 refining Methods 0.000 description 1
• 238000000611 regression analysis Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229940085605 saccharin sodium Drugs 0.000 description 1
• 229960002181 saccharomyces boulardii Drugs 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 238000013341 scale-up Methods 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000007790 scraping Methods 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 229940001593 sodium carbonate Drugs 0.000 description 1
• 235000017550 sodium carbonate Nutrition 0.000 description 1
• 229960002668 sodium chloride Drugs 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229960001790 sodium citrate Drugs 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
• 235000010334 sodium propionate Nutrition 0.000 description 1
• 239000004324 sodium propionate Substances 0.000 description 1
• 229960003212 sodium propionate Drugs 0.000 description 1
• 229940080313 sodium starch Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 229940001941 soy protein Drugs 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000005070 sphincter Anatomy 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
• 229940114926 stearate Drugs 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 238000011146 sterile filtration Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 150000003440 styrenes Chemical class 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000003894 surgical glue Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000009182 swimming Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 210000001258 synovial membrane Anatomy 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 229960003080 taurine Drugs 0.000 description 1
• 208000012271 tenesmus Diseases 0.000 description 1
• ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 238000001931 thermography Methods 0.000 description 1
• 229920001169 thermoplastic Polymers 0.000 description 1
• 239000004416 thermosoftening plastic Substances 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 239000003106 tissue adhesive Substances 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 229960005196 titanium dioxide Drugs 0.000 description 1
• 235000010215 titanium dioxide Nutrition 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 239000001069 triethyl citrate Substances 0.000 description 1
• 235000013769 triethyl citrate Nutrition 0.000 description 1
• VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 210000003954 umbilical cord Anatomy 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000011870 unpaired t-test Methods 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229960003824 ustekinumab Drugs 0.000 description 1
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
• 238000009834 vaporization Methods 0.000 description 1
• 230000008016 vaporization Effects 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1